IP Library Granted Patent US 8,999,356
Granted Patent B1
US 8,999,356 · App. 11/291,234 · Granted Apr 7, 2015

Drug delivery system

Inventors: Jose E. Ramirez (Trumbull, CT); Austin McNamara (Villa Park, CA); Judy Hattendorf (Marina Del Ray, CA); Steve Goldner (Farmington Hills, MI)
Assignee: OMP, Inc.
A61K9/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,999,356
App. No.
11/291,234
Granted
Apr 7, 2015
Kind
B1
Abstract

Drug delivery systems and a treatment regimen that improves percutaneous absorption of topically applied drug or active agent is described. The method generally has three steps including pre-treating the surface of skin in need thereof; applying an active ingredient to the skin; and applying a post treatment agent to the skin. Pre-treatment agents, drugs and active ingredients, as well as post treatment agents are described.

Claims (21)

1. A method of improving the percutaneous absorption of an active ingredient topically applied to the skin of a user, the method comprising:

pre-treating the surface of skin;

applying an active ingredient to the skin; and

post-treating the skin, wherein post-treating includes applying one or more pre-treatment agents selected from the group consisting of cleansers, foaming gels, toners, exfoliants, vasodilators, pore opening compositions, and combinations thereof to the surface of the skin and wherein the percutaneous absorption of the active ingredient is increased compared to application of the active ingredient alone.

2. The method of claim 1 wherein the step of pre-treating the surface comprises applying a preparatory composition to the surface.

3. The method of claim 2 wherein the preparatory composition comprises cleanser, foaming gel, toner, exfoliant, vasodilator, pore opening composition, or combinations thereof.

4. The method of claim 3 wherein the exfoliant comprises glycolic acid, lactic acid, salicylic acid or combinations thereof.

5. The method of claim 3 wherein the pore opening composition comprises benzoyl peroxide, sulphur, resorcinol, retinoic acid, tretinoin, beta hydroxyl acids, alpha hydroxyl acids, salicylic acid, or combinations thereof.

6. The method of claim 3 wherein the vasodilator composition comprises amyl-nitrate, diazoxide, hydralizine, hydralazine/hydrochlorothiazide/reserpine, hydralazine/hydrochlorothiazide, minoxidil, bradykinin, niacin, 1,2,3-trinitrooxypropane, nitroglycerin, amlodipine, pentaerythritol, prostaglandin, nitric oxide, L-Arginine HCL, menthol, silver micronutrient, alpostadil, essential oil, or combinations thereof.

7. The method of claim 6 wherein the essential oil is selected from the group consisting of clary sage, geranium, fennel, lemongrass, lavender, rosemary, carrot, and combinations thereof.

8. The method of claim 2 wherein the preparatory composition comprises a moisturizer.

9. The method of claim 2 wherein the preparatory composition comprises a drying agent.

10. The method of claim 1 wherein the step of post-treating the skin further comprises applying a second active ingredient to the skin.

11. The method of claim 2 wherein the step of post-treating the skin comprises applying a second preparatory composition to the skin.

12. The method of claim 1 wherein the step of pre-treating the surface comprises the step of reducing the pH of the surface.

13. A method of improving the percutaneous absorption of an active ingredient topically applied to the skin of a user, the method comprising:

applying at least one pre-treatment agent to skin;

applying an active ingredient to treat the pre-treated skin; and

applying at least one post-treatment agent to the treated skin, wherein the at least one post-treatment agent is the same as the at least one pre-treatment agent.

14. The method of claim 13 , wherein the at least one pre-treatment agents is selected from the group consisting of cleanser, foaming gel, toner, exfoliant, vasodilator, pore opening composition, or combinations thereof.

15. The method of claim 13 , further comprising applying a second active ingredient to the post-treated skin.

Assignments (18)
SECURITY INTEREST Recorded Jul 30, 2026
From: OBAGI COSMECEUTICALS LLC
To: MIDCAP FINANCIAL TRUST, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 075464/0639 →
RELEASE OF SECURITY INTEREST Recorded Nov 17, 2025
From: TCW ASSET MANAGEMENT COMPANY LLC, AS ADMINISTRATIVE AGENT
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 072928/0385 →
PATENT SECURITY AGREEMENT Recorded Nov 17, 2025
From: OBAGI COSMECEUTICALS LLC
To: LSSF II OFFSHORE INVESTMENTS, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 073625/0459 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
RELEASE OF SECURITY INTEREST Recorded Mar 21, 2025
From: JPMORGAN CHASE BANK, N.A.
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 070592/0979 →
SECURITY INTEREST Recorded Mar 18, 2025
From: OBAGI COSMECEUTICALS LLC
To: TCW ASSET MANAGEMENT COMPANY LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070546/0595 →
SECURITY INTEREST Recorded Aug 1, 2022
From: OBAGI COSMECEUTICALS LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 060690/0148 →
RELEASE OF SECURITY INTEREST Recorded Jul 29, 2022
From: TCW ASSET MANAGEMENT COMPANY LLC
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 060668/0771 →
RELEASE OF SECURITY INTEREST Recorded Mar 19, 2021
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 055652/0735 →
SECURITY INTEREST Recorded Mar 16, 2021
From: OBAGI COSMECEUTICALS LLC
To: TCW ASSET MANAGEMENT COMPANY LLC, AS COLLATERAL AGENT
Reel/Frame 055613/0083 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 13, 2018
From: OBAGI COSMECEUTICALS LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 047873/0114 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2017
From: OMP, INC.
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 044829/0244 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BANK OF NEW YORK MELLON
To: OMP, INC.
Reel/Frame 044765/0176 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BARCLAYS BANK PLC
To: OMP, INC.
Reel/Frame 044440/0037 →
SECURITY INTEREST Recorded Jul 19, 2017
From: OMP, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0751 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Jul 29, 2013
From: OMP, INC.
To: GOLDMAN SACHS LENDING PARTNERS LLC
Reel/Frame 030919/0031 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2006
From: RAMIEREZ, JOSE E.; MCNAMARA, AUSTIN; HATTENDORF, JUDY; GOLDNER, STEVE
To: OMP, INC.
Reel/Frame 017540/0460 →
Continuity (1)
Provisional Application 60633407 · Dec 3, 2004